Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020

View ORCID ProfileAnup Malani, Sabareesh Ramachandran, Vaidehi Tandel, Rajeswari Parasa, S. Sudharshini, V. Prakash, Y. Yogananth, S. Raju, T.S. Selvavinayagam
doi: https://doi.org/10.1101/2021.02.03.21250949
Anup Malani
1University of Chicago, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Anup Malani
  • For correspondence: amalani@uchicago.edu
Sabareesh Ramachandran
2University of California San Diego, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vaidehi Tandel
3independent
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rajeswari Parasa
4IDFC Institute, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Sudharshini
5Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
V. Prakash
5Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Y. Yogananth
5Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Raju
5Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
T.S. Selvavinayagam
5Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

A population-representative serological study was conducted in all districts of the state of Tamil Nadu (population 72 million), India, in October-November 2020. State-level seroprevalence was 31.6%. However, this masks substantial variation across the state. Seroprevalence ranged from just 11.1% in The Nilgris to 51.0% in Perambalur district. Seroprevalence in urban areas (36.9%) was higher than in rural areas (26.9%). Females (30.8%) had similar seroprevalence to males (30.3%). However, working age populations (age 40-49: 31.6%) have significantly higher seroprevalence than the youth (age 18-29: 30.7%) or elderly (age 70+: 25.8%). Estimated seroprevalence implies that at least 22.6 million persons were infected by the end of November, roughly 36 times the number of confirmed cases. Estimated seroprevalence implies an infection fatality rate of 0.052%.

Competing Interest Statement

S. Sudharshini, V. Prakash, Y. Yogananth, and S. Raju, T.S. Selvavinayagam are employees of the Tamil Nadu Government. The study was funded and implemented by the Tamil Nadu government.

Funding Statement

The study was funded by the Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Directorate of Public Health & Preventative Medicine, Government of Tamil Nadu, and the Institutional Ethics Committee of Madras Medical College, Chennai, India.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Aggregated data are reported in the Supplement.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted February 08, 2021.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020
Anup Malani, Sabareesh Ramachandran, Vaidehi Tandel, Rajeswari Parasa, S. Sudharshini, V. Prakash, Y. Yogananth, S. Raju, T.S. Selvavinayagam
medRxiv 2021.02.03.21250949; doi: https://doi.org/10.1101/2021.02.03.21250949
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
SARS-CoV-2 Seroprevalence in Tamil Nadu in October-November 2020
Anup Malani, Sabareesh Ramachandran, Vaidehi Tandel, Rajeswari Parasa, S. Sudharshini, V. Prakash, Y. Yogananth, S. Raju, T.S. Selvavinayagam
medRxiv 2021.02.03.21250949; doi: https://doi.org/10.1101/2021.02.03.21250949

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (270)
  • Allergy and Immunology (552)
  • Anesthesia (135)
  • Cardiovascular Medicine (1757)
  • Dentistry and Oral Medicine (238)
  • Dermatology (173)
  • Emergency Medicine (312)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (659)
  • Epidemiology (10799)
  • Forensic Medicine (8)
  • Gastroenterology (590)
  • Genetic and Genomic Medicine (2949)
  • Geriatric Medicine (287)
  • Health Economics (534)
  • Health Informatics (1928)
  • Health Policy (836)
  • Health Systems and Quality Improvement (745)
  • Hematology (292)
  • HIV/AIDS (630)
  • Infectious Diseases (except HIV/AIDS) (12517)
  • Intensive Care and Critical Care Medicine (691)
  • Medical Education (299)
  • Medical Ethics (86)
  • Nephrology (324)
  • Neurology (2799)
  • Nursing (151)
  • Nutrition (433)
  • Obstetrics and Gynecology (559)
  • Occupational and Environmental Health (597)
  • Oncology (1466)
  • Ophthalmology (444)
  • Orthopedics (172)
  • Otolaryngology (257)
  • Pain Medicine (190)
  • Palliative Medicine (56)
  • Pathology (381)
  • Pediatrics (866)
  • Pharmacology and Therapeutics (366)
  • Primary Care Research (337)
  • Psychiatry and Clinical Psychology (2640)
  • Public and Global Health (5366)
  • Radiology and Imaging (1013)
  • Rehabilitation Medicine and Physical Therapy (595)
  • Respiratory Medicine (726)
  • Rheumatology (330)
  • Sexual and Reproductive Health (289)
  • Sports Medicine (279)
  • Surgery (327)
  • Toxicology (47)
  • Transplantation (150)
  • Urology (125)